tyrosine and thienopyridine

tyrosine has been researched along with thienopyridine in 5 studies

Research

Studies (5)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (80.00)	29.6817
2010's	1 (20.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Brinkman, WT; Chaikof, EL; Najibi, S; Terramani, TT	1
Bucha, E; Nowak, G; Schumann, A	1
Fontana, P	1
Boden, WE; Hoekstra, J; Miller, CD	1
Brazier, JE; Fox, KA; Schwenkglenks, M; Szucs, TD	1

Reviews

3 review(s) available for tyrosine and thienopyridine

Article	Year
Platelets: is aspirin sufficient or must we know how to pronounce abciximab? Seminars in vascular surgery, 2002, Volume: 15, Issue:4 Topics: Abciximab; Antibodies, Monoclonal; Arteriosclerosis; Aspirin; Blood Platelets; Clopidogrel; Endarterectomy, Carotid; Humans; Immunoglobulin Fab Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyridines; Ticlopidine; Tirofiban; Tyrosine	2002
[Update on antithrombotic treatments in arterial diseases]. Revue medicale suisse, 2007, Feb-07, Volume: 3, Issue:97 Topics: Abciximab; Antibodies, Monoclonal; Anticoagulants; Arteriosclerosis; Aspirin; Dipyridamole; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Pyridines; Thrombosis; Tirofiban; Treatment Outcome; Tyrosine	2007
ST-elevation myocardial infarction: the role of adjunctive antiplatelet therapy. The American journal of emergency medicine, 2008, Volume: 26, Issue:2 Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Clopidogrel; Electrocardiography; Eptifibatide; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyridines; Ticlopidine; Tirofiban; Tyrosine	2008

Other Studies

2 other study(ies) available for tyrosine and thienopyridine

Article	Year
Is platelet adhesion assay able to quantify drug-induced platelet dysfunction? Seminars in thrombosis and hemostasis, 2005, Volume: 31, Issue:4 Topics: Abciximab; Aged; Antibodies, Monoclonal; Blood Platelet Disorders; Blood Platelets; Cell Separation; Clopidogrel; Dose-Response Relationship, Drug; Eptifibatide; Female; Fibrinogen; Flow Cytometry; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Peptides; Platelet Adhesiveness; Platelet Aggregation; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Polymers; Pyridines; Ticlopidine; Tirofiban; Tyrosine	2005
Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2011, Volume: 14, Issue:1 Topics: Abciximab; Acute Coronary Syndrome; Antibodies, Monoclonal; Anticoagulants; Cost-Benefit Analysis; Decision Trees; Drug Therapy, Combination; Female; Health Care Costs; Heparin; Hirudins; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Models, Econometric; Myocardial Revascularization; Peptide Fragments; Platelet Glycoprotein GPIIb-IIIa Complex; Pyridines; Quality-Adjusted Life Years; Recombinant Proteins; Survival Analysis; Tirofiban; Tyrosine; United Kingdom	2011

Article

Year

Is platelet adhesion assay able to quantify drug-induced platelet dysfunction?

Seminars in thrombosis and hemostasis, 2005, Volume: 31, Issue:4

Topics: Abciximab; Aged; Antibodies, Monoclonal; Blood Platelet Disorders; Blood Platelets; Cell Separation; Clopidogrel; Dose-Response Relationship, Drug; Eptifibatide; Female; Fibrinogen; Flow Cytometry; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Peptides; Platelet Adhesiveness; Platelet Aggregation; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Polymers; Pyridines; Ticlopidine; Tirofiban; Tyrosine

2005

Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2011, Volume: 14, Issue:1

Topics: Abciximab; Acute Coronary Syndrome; Antibodies, Monoclonal; Anticoagulants; Cost-Benefit Analysis; Decision Trees; Drug Therapy, Combination; Female; Health Care Costs; Heparin; Hirudins; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Models, Econometric; Myocardial Revascularization; Peptide Fragments; Platelet Glycoprotein GPIIb-IIIa Complex; Pyridines; Quality-Adjusted Life Years; Recombinant Proteins; Survival Analysis; Tirofiban; Tyrosine; United Kingdom

2011